Bank of America
APLS

Bank of America’s Apellis Pharmaceuticals APLS Stock Holding History

Bank of America’s Portfolio APLS Stock Details APLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$47.9M Buy
1,190,864
+234,091
+24% +$5.04M ﹤0.01% 1628
2025
Q4 		$24M Sell
956,773
-520,752
-35% -$12.2M ﹤0.01% 2131
2025
Q3 		$33.4M Sell
1,477,525
-949,103
-39% -$22.1M ﹤0.01% 2108
2025
Q2 		$42M Sell
2,426,628
-704,808
-23% -$13M ﹤0.01% 1855
2025
Q1 		$68.5M Buy
3,131,436
+1,451,223
+86% +$40.1M 0.01% 1337
2024
Q4 		$53.6M Buy
1,680,213
+705,209
+72% +$21.2M ﹤0.01% 1433
2024
Q3 		$28.1M Sell
975,004
-20,065
-2% -$743K ﹤0.01% 2075
2024
Q2 		$38.2M Buy
995,069
+271,625
+38% +$12.3M ﹤0.01% 1657
2024
Q1 		$42.5M Buy
723,444
+289,107
+67% +$18.4M ﹤0.01% 1588
2023
Q4 		$26M Sell
434,337
-270,618
-38% -$13.7M ﹤0.01% 1890
2023
Q3 		$26.8M Buy
704,955
+295,113
+72% +$13M ﹤0.01% 1751
2023
Q2 		$37.3M Sell
409,842
-197,893
-33% -$17.1M ﹤0.01% 1522
2023
Q1 		$40.1M Buy
607,735
+138,723
+30% +$8M ﹤0.01% 1528
2022
Q4 		$24.3M Sell
469,012
-222,865
-32% -$11.8M ﹤0.01% 1858
2022
Q3 		$47.3M Buy
691,877
+323,561
+88% +$19.1M 0.01% 1305
2022
Q2 		$16.7M Sell
368,316
-13,642
-4% -$622K ﹤0.01% 2183
2022
Q1 		$19.4M Buy
381,958
+107,052
+39% +$4.73M ﹤0.01% 2162
2021
Q4 		$13M Sell
274,906
-5,066
-2% -$199K ﹤0.01% 2662
2021
Q3 		$9.23M Buy
279,972
+39,593
+16% +$2.22M ﹤0.01% 2943
2021
Q2 		$15.2M Sell
240,379
-117,600
-33% -$6.07M ﹤0.01% 2404
2021
Q1 		$15.4M Buy
357,979
+206,354
+136% +$9.76M ﹤0.01% 2286
2020
Q4 		$8.67M Buy
151,625
+27,681
+22% +$1.17M ﹤0.01% 2619
2020
Q3 		$3.74M Sell
123,944
-54,697
-31% -$1.63M ﹤0.01% 3172
2020
Q2 		$5.83M Sell
178,641
-34,479
-16% -$1.11M ﹤0.01% 2708
2020
Q1 		$5.71M Buy
213,120
+18,219
+9% +$647K ﹤0.01% 2551
2019
Q4 		$5.97M Buy
194,901
+45,710
+31% +$1.27M ﹤0.01% 3068
2019
Q3 		$3.59M Sell
149,191
-52,079
-26% -$1.43M ﹤0.01% 3521
2019
Q2 		$5.1M Buy
201,270
+8,643
+4% +$176K ﹤0.01% 3217
2019
Q1 		$3.76M Buy
192,627
+175,094
+999% +$2.75M ﹤0.01% 3438
2018
Q4 		$231K Buy
17,533
+10,407
+146% +$160K ﹤0.01% 5427
2018
Q3 		$126K Sell
7,126
-14,021
-66% -$259K ﹤0.01% 5758
2018
Q2 		$465K Buy
21,147
+20,097
+1,914% +$462K ﹤0.01% 4948
2018
Q1 		$23K Sell
1,050
-330
-24% -$6.49K ﹤0.01% 6335
2017
Q4 		$30K Buy
+1,380
New +$20.3K ﹤0.01% 6276

Other funds holding APLS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Bank of America's APLS Position: Q1 2026 in Review

Bank of America increased its Apellis Pharmaceuticals (APLS) stake by 24% in Q1 2026, buying an estimated $5.04M and bringing the position to 1,190,864 shares worth $47.9M. The position accounts for ﹤0.01% of the portfolio, ranked #1628.

Bank of America first reported a position in APLS in Q4 2017 and has held it in 34 quarters since. The position peaked at $68.5M in Q1 2025. 323 funds tracked by Wall St. Rank hold APLS as of Q1 2026.

  • Bank of America held 1,190,864 shares of Apellis Pharmaceuticals worth $47.9M as of Q1 2026.
  • Bank of America bought 234,091 Apellis Pharmaceuticals shares in Q1 2026, an estimated $5.04M.
  • Apellis Pharmaceuticals made up ﹤0.01% of Bank of America's portfolio in Q1 2026, its #1628 holding.
  • Bank of America first reported a position in Apellis Pharmaceuticals in Q4 2017 and has held it in 34 quarters since.
  • Bank of America's Apellis Pharmaceuticals position peaked at $68.5M in Q1 2025.
  • 323 funds tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q1 2026.

Based on Bank of America's 13F filing for Q1 2026, filed 18 May 2026.